# Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

> **NCT05387967** · PHASE4 · COMPLETED · sponsor: **National Institute of Cardiovascular Diseases, Pakistan** · enrollment: 121 (actual)

## Conditions studied

- Heart Failure, Systolic

## Interventions

- **DRUG:** Sacubitril/valsartan

## Key facts

- **NCT ID:** NCT05387967
- **Lead sponsor:** National Institute of Cardiovascular Diseases, Pakistan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387967, "Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05387967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*